32018-56-7

Basic information

• Product Name: 1-BENZYL-4-METHYL-1,2,3,6-TETRAHYDRO-PYRIDINE
• Synonyms: 1-BENZYL-4-METHYL-1,2,3,6-TETRAHYDRO-PYRIDINE;Pyridine, 1,2,3,6-tetrahydro-4-Methyl-1-(phenylMethyl)-;benzyl-4-Methyl-1,2,3,6-tetrahydropyridine
• CAS NO: 32018-56-7
• Molecular Formula: C₁₃H₁₇N
• Molecular Weight: 187.28078
• Mol File: 32018-56-7.mol
• Article Data: 23

Chemical Properties

• Boiling Point: 270℃
• Flash Point: 107℃
• Appearance: /
• Density: 1.000
• Vapor Pressure: 0.007mmHg at 25°C
• Refractive Index: 1.556
• PKA: 8.13±0.40(Predicted)
• CAS DataBase Reference: 1-BENZYL-4-METHYL-1,2,3,6-TETRAHYDRO-PYRIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-BENZYL-4-METHYL-1,2,3,6-TETRAHYDRO-PYRIDINE(32018-56-7)
• EPA Substance Registry System: 1-BENZYL-4-METHYL-1,2,3,6-TETRAHYDRO-PYRIDINE(32018-56-7)

Safety Data

• Hazardous Substances Data: 32018-56-7(Hazardous Substances Data)

Usage

General Description

1-Benzyl-4-methyl-1,2,3,6-tetrahydro-pyridine, also known as MPTP, is a synthetic compound that is primarily used in research to study the effects of Parkinson's disease. MPTP is known to cause symptoms similar to Parkinson's disease in humans and other primates, making it a useful tool for studying the mechanisms of the disease and developing potential treatments. The chemical is a highly toxic and potentially dangerous compound, as exposure to MPTP can cause irreversible damage to the brain and nervous system. Despite its toxic nature, MPTP has been valuable in advancing our understanding of Parkinson's disease and has led to the identification of new therapeutic targets for the condition.

InChI:InChI=1/C13H17N/c1-12-7-9-14(10-8-12)11-13-5-3-2-4-6-13/h2-7H,8-11H2,1H3

Upstream product

• 3970-66-9 1-benzyl-4-methyl-piperidin-4-ol 
• 3612-20-2 1-phenylmethyl-4-piperidone 
• 100-44-7 benzyl chloride 
• 108-89-4 picoline 
• 100-39-0 benzyl bromide 
• 20012-94-6 4-methyl-4-vinylazetidin-2-one 
• 1198423-01-6 N-benzyl-2-methyl-2-vinylazetidine 
• 23662-66-0 1-benzyl-4-methylpyridinium chloride 
• 127073-72-7 [Benzyl-(3-methyl-but-3-enyl)-amino]-acetonitrile 
• 57042-58-7 1-benzyl-1-bromo-4-methylpyridinium bromide 

Downstream Products

• 694-50-8 4-methyl-1,2,3,6-tetrahydropyridine 
• 103-29-7 1,1'-(1,2-ethanediyl)bisbenzene 
• 89873-54-1 1-Benzyl-4-methyl-3,6-dihydro-2H-pyridine 1-oxide 
• 384338-20-9 (rac, trans)-1-benzyl-4-methyl-piperidin-3-ol 
• 660403-89-4 1-benzyl-4-methyl-3,4-piperidinediol 
• 660403-89-4 (3R,4R)-1-Benzyl-4-methyl-piperidine-3,4-diol 
• 866929-74-0 (3R,4S)-1-benzyl-4-methyl-piperidine-3,4-diol 
• 384338-21-0 N-benzyl-3-hydroxy-4-methylpiperidinium toluene-4-sulfonate 
• 32018-96-5 1-benzyl-4-methyl-piperidin-3-one 
• 1228879-37-5 (3R,4R)-1-benzyl-N,4-dimethylpiperidine-3-amine dihydrochloride 
• 1228879-37-5 C₁₄H₂₂N₂*ClH 
• 384338-20-9 1-benzyl-4-methylpiperidin-3-ol 

Relevant articles and documents

COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES

The present invention provides a compound of formula (Ia) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, solid forms, combinations of pharmacologically active agents, pharmaceutical compositions and methods of using such compounds and solid forms thereof to treat or prevent parasitic diseases, for example malaria.

TRICYCLIC DEGRADERS OF IKAROS AND AIOLOS

Tricyclic cereblon binders for the degradation of Ikaros or Aiolos by the ubiquitin proteasome pathway for therapeutic applications are described.

N-benzyl-tetrahydropyridine compound and preparation method thereof

The invention provides an N-benzyl-tetrahydropyridine compound and a preparation method thereof, and the preparation method comprises the following steps: S1, adding benzyl bromide into a pyridine compound to carry out nucleophilic substitution reaction t